Theratechnologies Inc. (THTX)
NASDAQ: THTX · IEX Real-Time Price · USD
1.340
+0.040 (3.08%)
May 2, 2024, 2:49 PM EDT - Market closed
Theratechnologies Revenue
Theratechnologies had revenue of $57.85M in the twelve months ending February 29, 2024, down -4.06% year-over-year. Revenue in the quarter ending February 29, 2024 was $12.03M, a -18.39% decrease year-over-year. In the fiscal year ending November 30, 2023, Theratechnologies had annual revenue of $59.25M, a decrease of -1.57%.
Revenue (ttm)
$57.85M
Revenue Growth
-4.06%
P/S Ratio
1.06
Revenue / Employee
$561,690
Employees
103
Market Cap
61.61M USD
Revenue Chart
* The company reports in CAD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2023 | 59.25M | -943.96K | -1.57% |
Nov 30, 2022 | 60.19M | 5.64M | 10.35% |
Nov 30, 2021 | 54.55M | 3.74M | 7.36% |
Nov 30, 2020 | 50.81M | 3.28M | 6.90% |
Nov 30, 2019 | 47.53M | 13.53M | 39.81% |
Nov 30, 2018 | 34.00M | 4.94M | 17.01% |
Nov 30, 2017 | 29.06M | 21.94M | 308.18% |
Nov 30, 2013 | 7.12M | -6.54M | -47.88% |
Nov 30, 2012 | 13.66M | -985.25K | -6.73% |
Nov 30, 2011 | 14.64M | -16.44M | -52.90% |
Nov 30, 2010 | 31.09M | 14.56M | 88.06% |
Nov 30, 2009 | 16.53M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bionano Genomics | 36.12M |
Sensus Healthcare | 24.41M |
Prenetics Global | 21.74M |
Turnstone Biologics | 19.31M |
Hyperfine | 11.03M |
THTX News
- 11 hours ago - Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting - GlobeNewsWire
- 17 days ago - Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders - GlobeNewsWire
- 21 days ago - Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewsWire
- 22 days ago - Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 - GlobeNewsWire
- 24 days ago - Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform - GlobeNewsWire
- 27 days ago - Theratechnologies Appoints Elina Tea to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 5 weeks ago - Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform - GlobeNewsWire